A retrospective on the Fen-Phen litigation reveals that lawyers pocketed the majority of a $200 million settlement, leaving victims with less than a quarter of the funds. The hosts investigate whether Ozempic is classified as a "biologic," which would grant it certain legal protections. They conclude that because it is not a biologic, it remains vulnerable to the same type of mass tort litigation that ended Fen-Phen.